KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Acadia Pharmaceuticals (ACAD) Retained Earnings (2016 - 2025)

Acadia Pharmaceuticals has reported Retained Earnings over the past 16 years, most recently at $1.4 million for Q4 2025.

  • Quarterly results put Retained Earnings at $1.4 million for Q4 2025, up 394.86% from a year ago — trailing twelve months through Dec 2025 was $1.4 million (up 394.86% YoY), and the annual figure for FY2025 was $1.4 million, up 394.86%.
  • Retained Earnings for Q4 2025 was $1.4 million at Acadia Pharmaceuticals, up from $989000.0 in the prior quarter.
  • Over the last five years, Retained Earnings for ACAD hit a ceiling of $1.4 million in Q4 2025 and a floor of -$2.5 billion in Q3 2023.
  • Median Retained Earnings over the past 5 years was -$950000.0 (2022), compared with a mean of -$1.0 billion.
  • Biggest five-year swings in Retained Earnings: crashed 6054423.68% in 2022 and later soared 1116.67% in 2024.
  • Acadia Pharmaceuticals' Retained Earnings stood at -$192000.0 in 2021, then tumbled by 1234041.15% to -$2.4 billion in 2022, then soared by 100.0% to $24000.0 in 2023, then soared by 1116.67% to $292000.0 in 2024, then soared by 394.86% to $1.4 million in 2025.
  • The last three reported values for Retained Earnings were $1.4 million (Q4 2025), $989000.0 (Q3 2025), and $406000.0 (Q2 2025) per Business Quant data.